Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Figure 6. Mexican family carrying the truncated mutant pR552*. (A) Pedigree Analysis: The family pedigree indicates that the father and all three sons present the disease. (B) Data from the family ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results